LAG3 Recombinant Rabbit mAb (Alexa Fluor? 594 Conjugate) (SDT-R159)

產(chǎn)品型號(hào)：S0B1644

更新時(shí)間：2025-07-14

廠商性質(zhì)：生產(chǎn)廠家

訪問(wèn)量：37

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對(duì)抗體病理/IHC抗體

查看全部產(chǎn)品

相關(guān)文章

蛋白激酶C 抗體套裝前來(lái)報(bào)到！

斯達(dá)特修飾抗體：“乳”虎添翼的實(shí)驗(yàn)利“甲”，讓PTM研究“乙”如“泛”掌

基因治療中重要的AAV抗體

探索mRNA疫苗生產(chǎn)流程：酶產(chǎn)品的核心角色

產(chǎn)品介紹

LAG3 （CD223） is the third IR to be targeted in the clinic. It is a potential cancer immunotherapeutic target due to its negative regulatory role on T cells and its capacity, in combination with PD1, to mediate a state of exhaustion [PMID: 26018646]. LAG3 up-regulation is required to control overt activation and prevent the onset of autoimmunity. However, persistent antigen exposure in the tumor microenvironment results in sustained LAG3 expression, contributing to a state of exhaustion manifest in impaired proliferation and cytokine production. The exact signaling mechanisms downstream of LAG3 and interplay with other IRs remains largely unknown. However, the striking synergy between LAG3 and PD1 observed in multiple settings, coupled with the contrasting intracellular cytoplasmic domain of LAG3 as compared with other IRs, highlights the potential uniqueness of LAG3. There are now four LAG3-targeted therapies in the clinic with many more in preclinical development.

上一個(gè)：S0C3016His tag OneStep ELISA Kit